Vaxart Inc
Cerrado
0
Resumen
Variación precio
24h
Mínimo
Máximo
Ingresos | -50M 5.2M |
|---|---|
Ventas | -65M 39M |
P/B Media del Sector | 4.063 51.415 |
BPA | 0.02 |
Margen de beneficios | 13.203 |
Empleados | 65 |
EBITDA | -53M 5.2M |
Próximas Ganancias | 12 ago 2026 |
|---|
Capitalización Mercado | -27M 157M |
|---|---|
Apertura anterior | 0 |
Cierre anterior | 0 |
Puntuación técnica
By Trading Central
Confianza
Bearish Evidence
Vaxart Inc Gráfico
Resultados pasados no son un indicador fiable de resultados futuros.
Noticias Relacionadas
Comparación entre iguales
Cambio de precio
Vaxart Inc previsión
Finanzas
Gastos de venta y administración
Gastos operativos
Beneficio antes de impuestos
Ventas
Coste de ventas
Beneficio bruto de ventas
Gasto por intereses de deuda
EBITDA
Beneficio operativo
$
Acerca de Vaxart Inc
Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.
